Introduction There has been spectacular devel opment in the treatment of patients with rheu matoid arthritis (RA) in the last 20 years. It is based on 3 important concepts, which now have become standard of care: 1 Development of new drugs: the arrival of bio logic agents to treat RA has been a major break through; although this medication is very costly, its efficacy is really impressive. 1 2 Treatment strategies: it has become clear from many clinical studies and observations that not an individual drug, but the timely combination of different drugs, given as a specific strategy, is much more effective than the previously used strategy of trying one drug after the other.
2,3
3 Treat to target: different studies have shown that targeting treatment to an individual patient, and thus adapting treatment every time when necessary, is much more efficacious than just treatment A or treatment B. 4 These concepts were timely reasons to for mulate new European League against Rheuma tism (EULAR) recommendations for the manage ment of RA with synthetic and bio logical disease modifying antirheumatic drugs (DMARDs). Under the guidance of Josef Smolen and Robert Landewe, over 30 European rheumato logists have been dis cussing the many results from literature searches and their own experience from daily practice. In the end, 3 so called overarching principles have been formulated, followed by 15 concrete recom mendations for the management of RA.
5
In the present review, overarching principles are discussed, the concrete recommendations are presented in the TABLE and explained in the text; sometimes my private comments are given, as re quested by the editors of this journal.
Overarching principles A. Rheumato logists are the specialists who should pri marily care for patients with RA. Different studies have shown that treatment by a rheumato logist has a much better effect, with regard to disease ac tivity and joint damage, than treatment given by a general practitioner, an inter nal medicine spe cialist, or an orthopedic surgeon. This, of course, does not implicate that other doctors and health professionals are not important in the treatment of RA patients, but does indicate that coordination of treatment should be with a rheumato logist. both with MTX monotherapy and defined res cue medication. One group was treated very in tensively: patients were evaluated every month and treatment was rapidly adapted to a maxi mum dose of 30 mg MTX weekly. The other group was randomized to conventional treatment: pa tients were seen every 3 months and treatment was adapted when physician and patient deemed it necessary. A computer program was developed to make the decisions in the intensive group, tak ing into account not only the actual disease activ ity, but also change from previous measurement. The group treated with the intensive schedule fared much better than the conventionally treated group. In the end, the total MTX dose was compa rable in both groups, because patients in the in tensive group were able to reduce their MTX dose when they reached remission.
Remission is, of course, the optimal target, and perhaps reachable in the majority of patients if we start treatment early enough. However, when the disease has become chronic for quite some time, remission is often no longer possible (in line with the "window of opportunity" discussion), but low disease activity should be our aim then.
3. MTX should be part of the first treatment strate gy in patients with active RA. From many com parative and strategy studies, it has become clear that MTX is the most effective drug given in ear ly RA, but also in established RA. We probably did not use the most adequate dosage in the past. Nowadays, we use the dose of 20 to 30 mg/week ly, which is quite well tolerated.
7 Subcutaneous administration of MTX might improve tolerance, especially if there are gastrointestinal complaints. Also the addition of 2 times weekly 5 mg folic acid is helpful in reducing adverse events, espe cially disturbances in liver function tests. MTX has been shown to have a favorable longterm safety profile and is used as a standalone treat ment, but also as part of most treatment strat egies. For instance, the effect of different tu mor necrosis factor α (TNFα) blockers on radio logical changes is clearly improved by the addi tion of MTX.
4. When MTX contraindications (or intolerance) are present, the following dMARds should be considered as part of the (first) treatment strategy: leflunomide, sulfasalazine (ssZ), or injectable gold. Though clear comparator studies are missing, it is general ly felt, based on longterm efficacy data of differ ent drugs, that MTX is by far the most effective DMARD. However, when there are contraindica tions, such as liver problems, leflunomide, SSZ, or injectable gold can be given as a standalone treatment in RA. Their efficacy as monotherapy is limited; therefore, they are preferably used as part of a treatment strategy. Studies on the added val ue of hydroxychloroquine as part of a treatment strategy are not convincing; therefore, hydroxy chloroquine did not receive a prominent place in the current EULAR recommendations.
B. Treatment of patients with RA should aim at the best care and must be based on a shared decision between the patient and the rheumato logist. Best care is the final goal in the EULAR recommendations; we should aim to deliver this care to all patients with RA in Europe. In the treat ment of every chronic disease, involvement of patients in the decision making progress is im portant; this is also para mount in the treatment of RA.
C. RA is expensive as far as medical and productiv ity costs are concerned, both should be considered by the treating rheumato logist. The more the ad vantages of especially bio logical drugs become clear, the more these drugs are used. The cost of these drugs is growing rapidly. Not many coun tries are able to supply them unlimited to all pa tients that need them. Even in such countries as the Netherlands, where up to 30% of RA patients use these drugs, financial constraints are felt and unpopular government rulings are pending. It should be a mission of the European rheumato logists to make sure that those patients who re ally need these expensive drugs are indeed able to receive them. It is expected that clinical trials will be started to evaluate whether it is possible in certain patients to decrease the dosage of these drugs or even to stop them completely, when pa tients have come into remission.
Recommendations In the TABLE, the 15 EULAR recommendations for the management of RA are given.
1. Treatment with synthetic dMARds should be start ed as soon as the diagnosis of RA is made Differ ent studies have shown that the earlier the ther apy with DMARDs is started, the more effica cious it is. 2 In our own department in Utrecht, the Netherlands, DMARDtherapy (methotrex ate [MTX] ) is started as soon as the clinical diag nosis of RA is made. It is expected that the new EULAR/American College of Rheumatology cri teria for the diagnosis of RA will help us identi fy these patients as soon as possible.
6 We often speak of the "window of opportunity", mean ing that there is only a limited space of time that we are able to make a real difference in the out come for our patients. If we wait too long, it will become very difficult to reach remission and to prevent damage. Therefore, the sooner we start, the better.
2. Treatment should be aimed at reaching a target of remission or low disease activity as soon as possible in every patient; as long as the target has not been reached, treatment should be adjusted by frequent checkups (every 1 to 3 months) and strict monitoring.
The CAMERA study has convincingly shown that tight control in patients with early RA is indeed feasible, even in very crowded outpatient clin ics.
4 In that particular study, 300 patients were randomized to 2 different treatment strategies, daily seems to be effective, especially in the first 6 months of the disease. In studies where GCs were used for 26 weeks or longer, it has been shown that also after stopping the GCs, after up to 5 years, still a significant difference in erosive damage existed in favor of the groups original ly treated with GCs. From different randomized controlled studies, it has been extrapolated that the symptomatic effect of GCs starts to wane af ter 6 months. Therefore, it seems reasonable to try to stop the added GCs after about 6 months, of course based on the individual patient. In most current combination therapies, GCs have become part of that regimen. Of course, we should be very well aware of the possible adverse events of GCs. Specific EULAR recommendations are for mulated how to use GCs as safely and as effec tively as possible. 7. If the treatment target is not achieved with the first dMARd strategy, addition of a bio logical dMARd should be considered when poor prognostic factors are present; in the absence of poor prognostic fac tors, switching to another synthetic dMARd strat egy should be considered. Not all risk factors for a bad prognosis of RA are as yet known. Associ ations have been found with (high) rheumatoid factor, including anticyclic citrullinated peptide antibody, high disease activity at start, early pres ence of erosions, and some genetic markers. It is expected that we will learn more about these risk 5. In dMARdnaïve patients, irrespective of the ad dition of glucocorticoids (GCs), synthetic dMARd monotherapy rather than combination therapy of synthetic dMARds may be applied. Though many rheumato logists firmly believe that DMARDs are more effective in DMARDnaïve patients as part of a combination therapy, there is insufficient evidence in literature to really make this state ment. Apart from studies in which GCs vs. pla cebo were added to DMARDs, no studies adding one DMARD or placebo to another DMARD have been performed. Therefore, it seems feasible to give a patient in this setting monotherapy with a DMARD, provided that tight control and mon itoring is installed. For the research agenda this is an important question that needs to be solved in the future.
6. GCs added at lowtomoderately high doses to syn thetic dMARd monotherapy (or combinations of syn thetic dMARds) provide benefit as initial shortterm treatment, but should be tapered as rapidly as clin ically feasible. In the last years, good evidence for the beneficial effects of GCs, especially ear ly in the disease, has been provided. Different studies, summarized in a Cochrane review, have shown that GCs, when added to other drugs, such as MTX, gold, and other DMARDs, are able to re duce the progression of erosive disease.
8 The dos es used varied between 5 and 10 mg daily; based on the effect sizes, a dose between 7.5 and 10 mg 
3 MTX should be part of the first treatment strategy in patients with active RA.
4 When MTX contraindications (or intolerance) are present, the following DMARDs should be considered as part of the (first) treatment strategy: leflunomide, SSZ, or injectable gold.
In DMARD-naïve patients, irrespective of the addition of GCs, synthetic DMARD monotherapy rather than combination therapy of synthetic DMARDs may be applied.
6 GCs added at low-to-moderately high doses to synthetic DMARD monotherapy (or combinations of synthetic DMARDs) provide benefit as initial short-term treatment, but should be tapered as rapidly as clinically feasible.
7 If the treatment target is not achieved with the first DMARD strategy, addition of a bio logical DMARD should be considered when poor prognostic factors are present; in the absence of poor prognostic factors, switching to another synthetic DMARD strategy should be considered.
8 In patients responding insufficiently to MTX and/or other synthetic DMARDs with or without GCs, bio logical DMARDs should be started; current practice would be to start a TNF inhibitor combined with MTX.
9 Patients with RA for whom a first TNF inhibitor has failed, should receive another TNF inhibitor, abatacept, rituximab, or tocilizumab.
10 In cases of refractory severe RA or contraindications to bio logical agents or the previously mentioned synthetic DMARDs, the following synthetic DMARDs might be also considered as monotherapy or in combination with some of the above: azathioprine, cyclosporin A (or exceptionally cyclophosphamide).
11 Intensive medication strategies should be considered in every patient, although patients with poor prognostic factors have more to gain.
12 If a patient is in persistent remission, after having tapered GCs, one can consider tapering bio logical DMARDs, especially if this treatment is combined with a synthetic DMARD.
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In cases of sustained long-term remission, cautious titration of synthetic DMARD dose could be considered, as a shared decision between the patient and the doctor.
14 DMARD-naïve patients with poor prognostic markers might be considered for combination therapy of MTX plus a bio logical agent.
15 When adjusting treatment, apart from disease activity, factors such as progression of structural damage, comorbidities, and safety concerns should be taken into account.
Abbreviations: DMARD - disease-modifying antirheumatic drug, EULAR - European League against Rheumatism, GC - glucocorticoid, MTXmethotrexate, RA - rheumatoid arthritis, SSZ - sulfasalazine, TNF -tumor necrosis factor scientific data to make evidencebased choices in this regard, though it has been suggested that Bcell depletion is a more logical choice in patients that are rheumatoidfactor positive.
10. In cases of refractory severe RA or contraindica tions to bio logical agents or the previously mentioned synthetic dMARds, the following synthetic dMARds might be also considered as monotherapy or in combina tion with some of the above: azathioprine, cyclosporin A (or exceptionally cyclophosphamide). Despite all treatment modalities discussed above, there are still patients with refractory RA in whom these treat ment strategies fail. In these patients, it is worth while to try azathioprine, cyclosporin A, or, in ex ceptional cases, cyclophosphamide. Also in cases of financial constraints, the use of azathioprine or cy closporin A in individual cases could be considered before bio logicals are given. In these exceptional cas es, arguments for this choice would not be evidence in literature, but costs. 13. In cases of sustained longterm remission, cau tious titration of synthetic dMARd dose could be considered, as a shared decision between the pa tient and the doctor. When remission is sustained, after stopping the bio logical DMARD it might be worthwhile to taper the other DMARDs. A gen eral advice would be to do this very slowly. There have been studies on tapering DMARDs when pa tients were in remission; however, at that time remission was not as well defined as it is now.
10
We now have more sophisticated measures to de cide whether or not a patient is in remission. As soon as consensus on the definition of remission, and how to measure it, is reached, studies will be undertaken to decrease treatment in those pa tients who are truly in remission. Personally, when a patient with longstanding RA is in "clinical remission" with for instance 15 mg MTX weekly, I am not in a hurry to taper this medication, especially when the patient has no complaints about this treatment.
factors in the coming years, when personalized treatment will also be introduced in RA. It is sug gested that if an RA patient who does not have any of the well known risk factors and fails his/ her first DMARD (MTX), it is worthwhile to try another DMARD first. However, if 1 or more risk factors are present, it is suggested to start a bio logical, namely a TNFα inhibitor. Logical choic es for a second DMARD are leflunomide, SSZ, or injectable gold. Frequent monitoring of these patients is recommended, to prevent losing too much time awaiting an improvement that is not to come. However, the percentage of patients re sponding to a second DMARD warrants this step in the lower risk group.
In patients responding insufficiently to MTX and/or other synthetic dMARds with or without
GCs, bio logical dMARds should be started; current practice would be to start a TNF inhibitor which should be combined with MTX. TNFα block ers have been shown to be very effective in pa tients with active RA. The introduction of these drugs at the end of the last century has complete ly changed clinical rheumatology. As could be ex pected, most impressive gains were observed in those patients with most severe disease. Rough ly, it can be stated that ⅓ of RA patients respond extremely well; ⅓ respond well, and the last ⅓ do not respond at all. Therefore, it is very important to make an adequate use of these drugs: deter mine which patients will respond best, but also decide in which patients it is better to stop be cause the drug is ineffective. Apart from the clear clinical effects, improvement has been noted in less erosive damage and in the possibility of pa tients to participate more in their work and so cial activities. During the years of development of the TNFα blockers, these drugs have become more and more humanized, and the frequency in which the drugs need to be given subcutane ously has decreased, from twice a week to only once a month.
Different products have their own characteri stics. There is insufficient data to predict which patient will respond best to a specific drug. Rese arch is now ongoing in targeting specific patient groups for specific drugs. This would have clear ad vantages, namely not losing "window of opportu nity" time by giving a patient an inadequate drug, but also not spending money on a drug that is not working in that specific patient. As mentioned be fore, the efficacy of TNFα blockers is increased by adding MTX, not only with regard to radio logical damage but also with regard to the occurrence of antibodies against TNFα blockers.
9. Patients with RA in whom the first TNF inhibi tor has failed should receive another TNF inhibitor, abatacept, rituximab, or tocilizumab. Present data suggest that it is worthwhile to try another TNF blocker when the first one has failed. However, there are good reasons to choose one of the other bio logicals. At present, we do not have adequate 14. dMARdnaïve patients with poor prognostic markers might be considered for combination ther apy of MTX plus a bio logical agent. We all know patients with a very aggressive early RA. These patients have a poor prognosis, and there is good reason to start treatment as intensive and as soon as possible, despite limited data from literature. Indirect data from the BEST study show that pa tients treated with a high dose of GCs have com parable results to patients starting with a bio logical straight away. 11 Obviously, in this group of patients, GCs will have a place as well.
15. When adjusting treatment, factors apart from disease activity, such as progression of structural damage, comorbidities, and safety concerns should be considered. This recommendation advertis es good clinical practice. Of course comorbidities and safety concerns should be part of every choice made in the treatment of patients with RA. How ever, we should realize that RA can be a very ag gressive disabling disease; thus, a careful balance between the disease and its treatment should be made, with all relevant factors considered.
In order to help physicians and patients in indi vidual decisions, the FIGuRE provides an algorithm based on the EULAR recommendations. 5
Conclusion Present times are very inter esting for RA patients and for those who care for them. We have gained a lot; we can probably gain even more. However, we have to be aware of the finan cial constraints brought about by this progress. It has been proved in different studies that adequate use of anchor drugs, such as MTX and GCs, may be beneficial for many patients. It will be a chal lenge for the coming years to find the optimal bal ance in the treatment of our patients. The new area of personalized medicine, in which we will be able to diagnose RA very early, to make a re liable prognosis early in the disease, and to pre dict response to different treatment regimens, will help us reach these goals.
